Women receive more inpatient resections and ablations for hepatocellular carcinoma than men

Table 1 Demographic and clinical parameters in patients with hepatocellular carcinoma grouped by gender between 2010 and 2013

	Male (n = 45908)		Female (n = 16674)		P value
	n	%	n	%
Age (yr)					< 0.001
≤ 64	28784	62.70	7847	47.06
65-79	13683	29.81	6226	37.34
≥ 80	3441	7.50	2602	15.60
Race					0.865
Caucasian	23845	51.94	8583	51.47
African-American	7172	15.62	2554	15.32
Hispanic	6572	14.32	2416	14.49
Asian	3660	7.97	1316	7.89
Others/unknown	4658	10.15	1806	10.83
Primary payer					< 0.001
Medicare	18592	40.50	8803	52.79
Medicaid	9198	20.04	2426	14.55
Private insurance	12757	27.79	4139	24.82
Self-pay	2771	6.04	695	4.17
No charges	319	0.70	76	0.46
Unknown/other	2270	4.95	535	3.21
Geographic region					0.006
Northeast	10910	23.77	3643	21.85
Midwest	7929	17.27	3311	19.86
South	16808	36.61	5961	35.75
West	10261	22.35	3759	22.54
Hepatitis C	8449	18.40	2359	14.15	< 0.001
Hepatitis B	2839	6.18	580	3.48	< 0.001
Alcohol	9102	19.83	923	5.53	< 0.001
NASH	15935	34.71	6044	36.24	0.126
Primary sclerosing cholangitis	394	0.86	188	1.13	0.171
Primary biliary cirrhosis	51	0.11	123	0.74	< 0.001
Autoimmune	50	0.11	136	0.81	< 0.001
Other	17124	37.30	8542	51.23	< 0.001
Liver decompensation Features					< 0.001
Zero	24826	54.08	10538	63.20
One	13348	29.08	4308	25.84
Two	6126	13.34	1539	9.23
Three or greater	1608	3.50	289	1.73
Metastasis					0.627
None	38219	83.25	13992	83.92
Single site	5954	12.97	2052	12.30
Two or more sites	1735	3.78	630	3.78
Elixhauser comorbidity Score
< 3	22662	49.36	7982	47.87	0.141
≥ 3	23246	50.64	8692	52.13
Treatment options
Transplant	1553	3.38	492	2.95
Resection	4945	10.77	2551	15.30
Ablation	2702	5.89	1103	6.62
TACE	3701	8.06	1241	7.44
Noninvasive treatment	33007	71.90	11288	67.70

NASH: Non-alcoholic steatohepatitis; TACE: Transcatheter arterial chemoembolization.